Cardiology Solutions
Genetic testing for hereditary cardiovascular conditions and risk assessment
Service · HybridCompany source
Company profile
About Invitae
Invitae is a leading genetic testing company that has joined forces with Labcorp to make innovative genetic testing more accessible and actionable for patients and healthcare providers. The company's mission is to improve health and improve lives by providing comprehensive genetic information that informs every stage of life. Invitae offers broad test offerings across multiple clinical areas including oncology, women's health, pediatrics and rare diseases, cardiology, and neurology. The company has been chosen by over 5 million patients and their providers, establishing itself as a trusted source for genetic testing services. Invitae's approach combines flexible billing options, coverage by most health plans, and access to Labcorp's nationwide network of patient service centers. A key differentiator is the inclusion of genetic counseling services at no additional cost for patients in the US, US territories, and Canada. The company provides extensive clinical practice resources, including gene-specific medical management guides and result interpretation tools developed by experts based on standard medical management guidelines. These resources help healthcare providers understand test results and determine appropriate next steps for patients who test positive for genetic variants. Through its integration with Labcorp, Invitae continues to advance the field of genetics while improving patient care and access to personalized medicine.
Company description Invitae official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Work at Invitae?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiology conditions
- Cardiovascular genetic disorders
- Hereditary cancer syndromes
- Metabolic disorders
- Neurodevelopmental conditions
- Neurology conditions
- Oncology
- Pediatric and rare diseases
- Women's health conditions
Who it serves
- Clinicians
- Health systems
- Healthcare providers
- Patients
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsCanada · United States · US territories
Company sourceOfficial website
Company milestones
Platform expansion
Acquisition by and integration with Labcorp to expand access through nationwide network of patient service centers
Partnerships
Recorded partners
- Labcorp (parent company/acquirer)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Clinical Practice Resources
Gene-specific medical management guides and clinical resources for healthcare providers
Platform · Cloud SaaSCompany source
Genetic Counseling Services
Complimentary genetic counseling included with testing for US, US territories, and Canadian patients
Service · HybridCompany source
Invitae Genetic Testing Services
Comprehensive genetic testing services for personalized healthcare across multiple specialties
Service · HybridCompany source
Neurology Genetic Testing
Genetic testing for neurological conditions and neurodegenerative disorders
Service · HybridCompany source
Oncology Genetic Testing
Genetic testing services for cancer risk assessment and treatment planning
Service · HybridCompany source
Pediatrics & Rare Diseases Genetic Testing
Genetic testing for pediatric patients and rare disease diagnosis
Service · HybridCompany source
Women's Health Genetic Testing
Genetic testing services focused on women's health conditions and reproductive planning
Service · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Updates to gene-disease classifications and inheritance patterns for porphyrias.Molecular genetics and metabolism · Jul 1, 2026
Germline Cancer Testing in Unselected Patients With Neuroendocrine Neoplasms: A Multi-center Prospective Study.Pancreas · Jun 4, 2026
Ensuring equity in reproductive carrier screening of CFTR with increasing population diversity.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · Jun 1, 2026
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.Prostate cancer and prostatic diseases · Jun 1, 2026
Genetic findings and health care utilization among individuals undergoing population genomic screening for actionable hereditary disorders.Genetics in medicine : official journal of the American College of Medical Genetics · May 19, 2026
Diagnostic yield of exome reanalysis over time: Contribution of reevaluation type, timing, and patient phenotype.Genetics in medicine : official journal of the American College of Medical Genetics · May 1, 2026
Clinical validation
Clinical-trial records
Early Check: Expanded Screening in NewbornsNCT03655223 · Mentioned · ACTIVE NOT RECRUITING
FaCT Trial (Facilitated Cascade Testing Trial)NCT04613440 · Mentioned · ACTIVE NOT RECRUITING
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.NCT05649072 · Mentioned · RECRUITING
Long Term Outcomes After Vestibular ImplantationNCT06500975 · Mentioned · RECRUITING
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia DiagnosisNCT06339190 · Sponsor · RECRUITING
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
5+ million patients served
Total patients and providers who have chosen Invitae for genetic testing
Coverage by most health plans
Insurance accessibility for genetic testing services
5+ million patients
Genetic testing services chosen by patients and their healthcare providers
5+ million patients served
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Invitae
Recent articles published on Invitae's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.